Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893 ·Status: TERMINATED ·Phase: PHASE4

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

NCT02407756 ·Status: COMPLETED ·Phase: PHASE2

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914 ·Status: COMPLETED ·Phase: PHASE3

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277769 ·Status: COMPLETED ·Phase: PHASE3

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897 ·Status: RECRUITING ·Phase: PHASE3

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03912259 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882 ·Status: COMPLETED ·Phase: PHASE3

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151 ·Status: COMPLETED ·Phase: PHASE1

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

NCT06039241 ·Status: RECRUITING

A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)

NCT04220411 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Skin Barrier Abnormalities and Oxidative Stress Response

NCT04606615 ·Status: UNKNOWN

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

NCT02210780 ·Status: COMPLETED ·Phase: PHASE2

The Effects of Dupilumab on Allergic Contact Dermatitis

NCT03935971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05507580 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

NCT03607422 ·Status: COMPLETED ·Phase: PHASE3

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988 ·Status: COMPLETED ·Phase: PHASE2

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

NCT01949311 ·Status: COMPLETED ·Phase: PHASE3

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870 ·Status: COMPLETED ·Phase: PHASE4

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

NCT02395133 ·Status: COMPLETED ·Phase: PHASE3

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2